Human Molecular Genetics, Vol 7, 831-838, Copyright © 1998 by Oxford University Press
J Guidotti, S Akli, L Castelnau-Ptakhine, A Kahn and L Poenaru
Tay-Sachs disease is a severe neurodegenerative disorder due to mutations
in the HEXA gene coding for the alpha-chain of the alpha-beta heterodimeric
lysosomal enzyme beta-hexosaminidase A (HexA). Because no treatment is
available for this disease, we have investigated the possibility of
enzymatic correction of HexA-deficient cells by HEXA gene transfer. Human
HEXA cDNA was subcloned into a retroviral plasmid generating to G.HEXA
vector. The best Psi-CRIP producer clone of G.HEXA retroviral particles was
isolated, and murine HexA-deficient fibroblasts derived from hexa -/- mice
were transduced with the G.HEXA vector. Transduced cells overexpressed the
alpha-chain, resulting in the synthesis of interspecific HexA (human
alpha-chain/murine beta- chain) and in a total correction of HexA
deficiency. The alpha-chain was secreted in the culture medium and taken up
by HexA-deficient cells via mannose-6-phosphate receptor binding, allowing
for the restoration of intracellular HexA activity in non-transduced cells.
ARTICLES
Retrovirus-mediated enzymatic correction of Tay-Sachs defect in transduced and non-transduced cells
Institut Cochin de Genetique Moleculaire (ICGM), U129 INSERM, Universite Rene Descartes-Paris V, CHU Cochin-Port Royal, Paris, France. guidotti@cochin.inserm.fr
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
S. Martino, C. Emiliani, B. Tancini, G. M. Severini, V. Chigorno, C. Bordignon, S. Sonnino, and A. Orlacchio Absence of Metabolic Cross-correction in Tay-Sachs Cells. IMPLICATIONS FOR GENE THERAPY J. Biol. Chem., May 31, 2002; 277(23): 20177 - 20184. [Abstract] [Full Text] [PDF] |
||||
